Douglas Johnson, Chairman, Director
Mr. Johnson has over
30 years of experience in the financing of both public and private
companies. Mr. Johnson has operated Canfund Ventures Corporation ("Canfund")
since 1982 as chief executive officer and president. Canfund is a venture
investor specializing in microcap and start-up companies and has extensive
investments in resources and technology companies. Mr. Johnson is the
president, chief executive officer and a director of Foundation Resources
Inc., and is also a director of both Search Capital Inc. and Ridgeline
Energy Services Inc., formerly Gavwest Resources Ltd., all of which are
listed on the TSX Venture Exchange.
Paul Brennan, Chief Executive Officer,
Director
Paul Brennan was appointed as the
Company's Chief Executive Officer on October 20, 2009. Since May 2009 Mr.
Brennan has been a Principal at Pacific BioPartners, a consulting company
focusing on supporting Biotech companies, including MIGENIX, with general
management and business development expertise. From August 2008 to April
2009 Mr Brennan was the CEO and a Board Member of Altair Therapeutics an
emerging biopharmaceutical company based in San Diego and focused on
developing inhaled therapeutics for respiratory diseases. In January 2007,
Mr Brennan joined Aspreva Pharmaceuticals as Senior Vice President, Business
Development, and was involved in the sale of the company to the Galenica
Corporation for $920 million. Between 2002 and 2007 Mr Brennan worked for
AnorMED, and held various positions in Business Development, Marketing and
General Management. Mr Brennan was a Board Member and was Acting-President
of AnorMED when it was sold to the Genzyme Corporation for $590 million.
Prior to joining AnorMED Mr Brennan worked for AstraZeneca in a number of
management positions in Business Development and Regulatory Affairs based in
Canada, Sweden and the UK. Mr Brennan has a M.Sc and B. Sc from Queen's
University in Kingston.
Bruce Schmidt, President
and Chief Financial Officer (Interim), Director
Bruce Schmidt was appointed
as the Company's President and Chief Executive Officer (interim) in
August 2008 and provides those services through his management company,
RJS Management Ltd. Mr. Schmidt ceased to be the Company’s Chief
Executive Officer effective October 20, 2009 with the appointment of Mr.
Brennan. From 1993 to 2000, Mr. Schmidt was a founder and Chief
Executive Officer of a University of British Columbia spin-off
biotechnology company focused on novel compounds for the treatment of
various cancers and neurological disorders. In 2000, Mr. Schmidt helped
found Genome British Columbia, a life-sciences research institute with
the objective of building world class genomics capabilities in Canada.
Mr. Schmidt has also served as a director for a number of high-tech and
biotech companies in Canada. Mr. Schmidt is currently a director of
GreenAngel Energy Corp. and En2Go International Ltd. Mr. Schmidt is a
past-director of the Canadian Healthcare Licensing Association,
past-Chair of the B.C. Nanotechnology Alliance and past-Chair of Life
Sciences British Columbia (formerly BCBiotech).
Pieter Dorsman, Director
Pieter Dorsman is President
and a Director of Redpeaks Management, Inc., a consulting firm in
Vancouver, which advises companies on finance and investment, corporate
development, legal structure and overall business strategies.
Through Redpeaks, Mr. Dorsman has taken on a number of financing and
restructuring mandates for technology, media and life science
companies. He is a co-founder and former CFO of Actenum Corp. and
currently an advisory board member and VP Corporate Development at
Aftercad Software Inc. Other Redpeaks clients have included Chrysalix
Energy and Ostara Nutrient Recovery Technologies. Mr. Dorsman currently
serves on the boards of ClearVision Technologies Inc. and MIGENIX Inc, a
TSX-listed biotechnology firm. Prior to establishing Redpeaks, Mr.
Dorsman held a number of senior positions at UBS in Hong Kong where he
was responsible for project and corporate finance mandates in the
South-East Asian region as well as in China. Prior to that he worked
for Barclays Bank PLC in Hong Kong and London where he started his
career. Mr. Dorsman holds a Master’s degree in Economic and Social
History for the Erasmus Universiteit in Rotterdam, The Netherlands where
he also studied law.
Mr. Rae is the chief
executive officer and president of iCo Therapeutics Inc., an ocular
development company he co-founded in 2005. Mr. Rae has spent a decade in the
biotechnology industry, formerly as chief financial officer with Ability
Biomedical Corporation. Mr. Rae has also served as vice president, Finance
and Corporate Affairs at Active Pass Pharmaceuticals. Previously, Mr. Rae
served as biotechnology equities analyst at Goepel Shields & Partners (now
Raymond James Ltd.), covering Canadian biotechnology stocks.